On schedule, Biomarin Pharmaceutical Inc. this week finished off the rolling new drug application (NDA) for exon 51-skipping drisapersen to treat Duchenne muscular dystrophy (DMD), situating the firm ...
Each week, this series shares MarionMade! stories of our many wonderful people, places, products and programs in the greater Marion community. To read more positive stories of Marion, or to share some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback